Jiangsu Food and Pharmaceutical Science College, Jiangsu, People's Republic of China.
Department of Pediatrics, Huai'an First Hospital Affiliated to Nanjing Medical University, Jiangsu, People's Republic of China.
Hematology. 2022 Dec;27(1):706-713. doi: 10.1080/16078454.2022.2080368.
Acute lymphoblastic leukemia is the most common malignant disease in children. CD34 and CD38 are expressed in both normal and leukemia cells, but studies of their prognostic associations in childhood acute lymphoblastic leukemia are limited. The aim of this study was to investigate the prognostic effect of CD34 CD38 leukemia cells in this childhood cancer.
From January 2014 to January 2019, children with newly diagnosed acute lymphoblastic leukemia were included in this study and followed up until July 2020. The participants were divided into CD34 and CD34 groups according to CD34 expression level at diagnosis, and the CD34 group was further divided into CD34 CD38 and CD34 CD38 subgroups based on CD38 expression level. We tracked clinical biological features, therapeutic outcomes, and other patient data for comparisons.
The OS and EFS did not differ significantly between the CD34 and CD34 groups (both > 0.05). CD34CD38 group and CD34CD38 group were further compared. OS differed significantly between these two groups (χ= 3.89, = 0.048), as did the recurrence rate (χ= 5.04, = 0.025), but EFS did not (χ= 1.45, > 0.05). Survival analysis in patients with recurrence showed a significantly higher OS for the CD34 CD38 group compared with the CD34 CD38 group (χ= 5.08, = 0.024). The CD34CD38 group and CD34CD38 group were matched for propensity scores. When recurrence was compared in the two groups after matching, the difference was statistically significant (< 0.001).
CD34 and CD34 expression does not differ by prognosis in children with acute lymphoblastic leukemia, but CD34 CD38 may indicate a poor prognosis.
急性淋巴细胞白血病是儿童中最常见的恶性疾病。CD34 和 CD38 在正常和白血病细胞中均有表达，但有关其在儿童急性淋巴细胞白血病中的预后相关性的研究有限。本研究旨在探讨 CD34CD38 白血病细胞在这种儿童癌症中的预后影响。
从 2014 年 1 月至 2019 年 1 月，纳入了患有新诊断的急性淋巴细胞白血病的儿童，并随访至 2020 年 7 月。根据诊断时的 CD34 表达水平，将参与者分为 CD34 组和 CD34 组，根据 CD38 表达水平，CD34 组进一步分为 CD34CD38 组和 CD34CD38 组。我们跟踪了临床生物学特征、治疗结果和其他患者数据以进行比较。
OS 和 EFS 在 CD34 组和 CD34 组之间无显著差异（均>0.05）。进一步比较 CD34CD38 组和 CD34CD38 组。这两组之间的 OS 有显著差异（χ=3.89，=0.048），复发率也有显著差异（χ=5.04，=0.025），但 EFS 无差异（χ=1.45，>0.05）。对复发患者的生存分析显示，CD34CD38 组的 OS 明显高于 CD34CD38 组（χ=5.08，=0.024）。CD34CD38 组和 CD34CD38 组进行倾向评分匹配。在匹配后比较两组的复发情况时，差异具有统计学意义（<0.001）。
CD34 和 CD34 的表达在儿童急性淋巴细胞白血病患者的预后中没有差异，但 CD34CD38 可能预示着不良预后。
